HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pirenzepine in duodenal ulcer. A six week, double-blind study.

Abstract
Thirty-eight of forty patients satisfactorily concluded a double-blind, placebo-controlled trial to study the effects of pirenzepine (100 mg/day) on duodenal ulcers. After six weeks of treatment 14 of 18 patients (78%) in the pirenzepine-treated group and 7 of 20 patients (35%) in the placebo groups were healed. There was a statistically significant difference (P less than 0.05). The relief of day-time and night-time pain was significantly greater in the pirenzepine-treated group. Pirenzepine-treated patients consumed significantly fewer antacid tablets. The tolerability of pirenzepine was good. Pirenzepine (100 mg/day for six weeks) should be an effective and safe treatment for duodenal ulcers.
AuthorsD Do, S Martelli, S Daniotti
JournalScandinavian journal of gastroenterology. Supplement (Scand J Gastroenterol Suppl) Vol. 72 Pg. 211-4 ( 1982) ISSN: 0085-5928 [Print] England
PMID6753115 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Antacids
  • Anti-Ulcer Agents
  • Benzodiazepinones
  • Pirenzepine
Topics
  • Adult
  • Antacids (therapeutic use)
  • Anti-Ulcer Agents (therapeutic use)
  • Benzodiazepinones (therapeutic use)
  • Clinical Trials as Topic
  • Double-Blind Method
  • Duodenal Ulcer (drug therapy)
  • Female
  • Humans
  • Male
  • Pain (drug therapy)
  • Pirenzepine
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: